Nutrition Research Center, Department of Clinical Nutrition, School of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Department of Clinical Nutrition, Faculty of Nutrition and Food Sciences, Nutrition Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Prostaglandins Other Lipid Mediat. 2024 Dec;175:106912. doi: 10.1016/j.prostaglandins.2024.106912. Epub 2024 Sep 27.
Several studies indicated the ameliorating effects of raloxifene supplementation on apolipoproteins and blood pressure, although others have conflicting findings. Therefore, the present study was conducted in order to accurately and definitively understands the effect of raloxifene on apolipoprotein AI (Apo-AI), apolipoprotein B (APoB), lipoprotein (a) (Lp (a)), systolic blood pressure (SBP) and diastolic blood pressure (DBP) in postmenopausal women.
A systematic literature search was conducted using scientific databases including PubMed, Scopus, Embase, and Web of Science and the Cochrane Library, through May 2024. The quality of studies was assessed using Cochrane tool. Random-effects meta-analysis was used to pool standardized mean differences (SMD) and 95 % CI for the outcomes.
Twenty trials, with interventions ranging from 6 to 144 weeks and 2825 participants, were included. Raloxifene supplementation demonstrated significant reductions in ApoB (SMD: -0.92; 95 % CI: -1.49 to -0.35; P = 0.001), and Lp (a) (SMD: -0.25; 95 % CI: -0.39 to -0.11; P < 0.001) while increasing Apo-AI levels (SMD: 0.29; 95 % CI: 0.22-0.36; P < 0.001). Conversely, no significant effects were observed on SBP (WMD: -0.49 mmHg; 95 % CI: -3.01-2.04; P = 0.706), and DBP (WMD: -0.81 mmHg; 95 % CI: -4.04-2.41; P = 0.621). Moreover, subgroup analysis indicated that raloxifene significantly decreased DBP in studies with intervention durations of >12 weeks.
This meta-analysis has shown that raloxifene supplementation may have beneficial effects on apolipoproteins in postmenopausal women. Future studies are needed to investigate the effect of raloxifene on health status in in postmenopausal women.
多项研究表明，雷洛昔芬补充剂可改善载脂蛋白和血压，但其他研究结果存在争议。因此，本研究旨在准确、明确地了解雷洛昔芬对绝经后妇女载脂蛋白 AI（Apo-AI）、载脂蛋白 B（APoB）、脂蛋白（a）（Lp（a））、收缩压（SBP）和舒张压（DBP）的影响。
使用包括 PubMed、Scopus、Embase 和 Web of Science 以及 Cochrane 图书馆在内的科学数据库进行系统文献检索，检索时间截至 2024 年 5 月。使用 Cochrane 工具评估研究质量。采用随机效应荟萃分析汇总结局的标准化均数差（SMD）和 95%置信区间。
共纳入 20 项试验，干预时间为 6 至 144 周，共有 2825 名参与者。雷洛昔芬补充剂可显著降低 ApoB（SMD：-0.92；95%CI：-1.49 至 -0.35；P=0.001）和 Lp（a）（SMD：-0.25；95%CI：-0.39 至 -0.11；P<0.001），同时增加 Apo-AI 水平（SMD：0.29；95%CI：0.22-0.36；P<0.001）。然而，SBP（WMD：-0.49mmHg；95%CI：-3.01-2.04；P=0.706）和 DBP（WMD：-0.81mmHg；95%CI：-4.04-2.41；P=0.621）无显著变化。此外，亚组分析表明，雷洛昔芬在干预时间>12 周的研究中可显著降低 DBP。
本荟萃分析表明，雷洛昔芬补充剂可能对绝经后妇女的载脂蛋白具有有益作用。需要进一步研究雷洛昔芬对绝经后妇女健康状况的影响。
